Conversely, the ATP-competitive AKT inhibitor capivasertib, when combined with fulvestrant, significantly improved progression-free survival in HR+-HER2− advanced breast cancer patients, particularly those who experienced disease progression during or after previous endocrine therapy, with or without a CDK4/6 inhibitor [29]. This evidence concerns the gene ERBB2 and breast cancer.